In patients with IBD, it is usually described a reduced bacterial diversity, with a decreased relative abundance of Firmicutes and an increase in pro-inflammatory bacteria, such as Proteobacteria, or adherent-invasive Escherichia coli or mucolytic bacteria such as Ruminococcus gnavus and Ruminococcus torques [37]
There are no published data for this
Most people will stop taking their GLP-1 eventually
More people are researching telehealth-based weight loss treatment options online, and detailed information about the Hims platform's physician-supervised weight management protocols is now accessible for anyone exploring their options
Investigators, semaglutide and cardiovascular outcomes in patients with type 2 diabetes
Our goal is transparency and ethical communication, helping patients understand the difference between evidence-backed medical treatments and emerging options still under investigation